Compare DigitalOcean Holdings Inc (DOCN) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DigitalOcean Holdings Inc vs Gilead Sciences, Inc. — how do they compare? DigitalOcean Holdings Inc trades at $132.1 (market cap $14.57B), while Gilead Sciences, Inc. trades at $151.08 (market cap $182.40B). The key difference: Gilead Sciences, Inc. is far larger — about 12.5× DigitalOcean Holdings Inc's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while DigitalOcean Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold DigitalOcean Holdings Inc for 43 Days and Gilead Sciences, Inc. for 111 Days on average.
| DOCN | GILD | |
|---|---|---|
Market Cap | $14.57B | $182.40B |
Volume | 2,261,786 | 4,469,821 |
Sector | Technology | Health |
52-Week High | $181.29 | $155.80 |
52-Week Low | $37.30 | $116.74 |
Typical Hold Time | 43 Days | 111 Days |
Enterprise Value | $15.33B | $205.46B |
Dividend Yield | — | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DigitalOcean trades at $127.28, down 2.89% today, with strong fundamentals including 29% revenue growth and consistent earnings beats. The company shows robust profitability with 57.22% gross margins and 23.27% net income margin, though valuation metrics remain elevated with P/E of 56.32. Recent AI-focused product launches and $725 million equipment financing facility support growth initiatives. Technical indicators show mixed signals with bullish oscillators but bearish moving averages, trading near key support at $126.
Outlook remains positive with analyst consensus target of $172.73 (35.7% upside) and 68% buy ratings. Key opportunities include AI-driven revenue growth and expanding cloud market share, while risks include high valuation, negative shareholder equity, and competitive pressure from larger cloud providers. The stock offers growth potential but requires careful monitoring of execution and market conditions.
Gilead Sciences (GILD) trades at $150.72, up 2.64% with a bullish technical signal and strong analyst support (65.5% buy ratings). Recent quarterly earnings have consistently beaten expectations, though Q2 2026 showed a significant loss. The company maintains robust operating cash flow ($10.02B in 2025) and is expanding HIV prevention access through new partnerships, positioning for growth despite a negative net income margin of -10.64%.
Outlook is cautiously optimistic with a consensus price target of $151.57, slightly above current levels. Key opportunities include pipeline advances in oncology and HIV treatments, while risks involve profitability volatility, high debt levels, and competitive pressures. The stock's valuation metrics suggest moderate pricing relative to earnings but elevated on sales and book value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DigitalOcean Holdings Inc
DigitalOcean Holdings Inc is a cloud computing platform offering on-demand infrastructure and platform tools for developers, start-ups and small and medium-sized businesses. The customers use the platform for a wide range of cases, such as web and mobile applications, website hosting, e-commerce, media and gaming, personal web projects, and managed services, among many others. The group has a business presence in North America, Europe, Asia and other countries.
Read more on DOCN →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
